Benaglutide ou Metformine pour le contrôle du poids dans l'obésité simple : effet et sécurité

Date de début de l'étude : 30 décembre 2017

Inclusion Criteria: (1)20 years old≤70 years old; (2) simple obesity, gender is not limited; (3) 28.0≤BMI≤37.5kg/m2; (4) Before the screening period, the body weight was controlled by lifestyle interventions (diet and exercise) for at least 3 months, and weight was decreased by \<5% from baseline; (5) Agree to sign the informed consent form; Exclusion Criteria: 1. Accurately diagnosed as having type 1 or type 2 diabetes according to the WHO 1999 diagnostic criteria; 2. Use weight loss drugs within 3 months before screening; 3. Metformin was used within the first 3 months of screening; 4. Malignant tumors (excluding basal cell or squamous cell carcinoma treated) within 5 years before enrollment 5. Alanine aminotransferase or aspartate aminotransferase \> 3 times the upper limit of normal or total serum bilirubin (TB) \>34.2 μmol/L (\>2 mg/dL) 6. Patients with moderate/severe renal impairment or end-stage renal disease (eGFR \< 60 mL/min/1.73 m2); male subjects with serum creatinine (Cr) ≥133 μmol/L (≥1.50 mg/dL Serum Cr in female subjects was ≥124 μmol/L (\>1.40 mg/dL); 7. Severe heart, lung, nervous, mental and infectious diseases; 8. Pregnancy, lactation and recent pregnancy plans; 9. Alternate or chronic systemic corticosteroid therapy, defined as treatment with any dose of systemic corticosteroids within 3 months of enrollment visit V1 \> 4 weeks 10. History of alcohol abuse, history of abuse of active drugs (opioids, analgesics, etc.) within 6 months before enrollment; 11. Give any other test drug within 30 days before enrollment or within 5 half-lives of other test drugs; 12. Patients with past history or family history of medullitary thyroid cancer (MTC) and patients with type 2 multiple endocrine tumor syndrome (MEN2); 13. Inability to tolerate benalutide, metformin; 14. Any influence of the investigator's judgment on enrollment.